[go: up one dir, main page]

PT2164993T - Métodos para produção e usos de populações de células multipotentes, populações de células pluripotentes, populações de célula diferenciadas e populações de células resistentes a vih - Google Patents

Métodos para produção e usos de populações de células multipotentes, populações de células pluripotentes, populações de célula diferenciadas e populações de células resistentes a vih

Info

Publication number
PT2164993T
PT2164993T PT87697611T PT08769761T PT2164993T PT 2164993 T PT2164993 T PT 2164993T PT 87697611 T PT87697611 T PT 87697611T PT 08769761 T PT08769761 T PT 08769761T PT 2164993 T PT2164993 T PT 2164993T
Authority
PT
Portugal
Prior art keywords
cell populations
hiv
production
methods
multipotent
Prior art date
Application number
PT87697611T
Other languages
English (en)
Inventor
b reid Christopher
Original Assignee
Reid Christopher B
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reid Christopher B filed Critical Reid Christopher B
Publication of PT2164993T publication Critical patent/PT2164993T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • AIDS & HIV (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
PT87697611T 2007-05-29 2008-05-28 Métodos para produção e usos de populações de células multipotentes, populações de células pluripotentes, populações de célula diferenciadas e populações de células resistentes a vih PT2164993T (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US93202007P 2007-05-29 2007-05-29
US93313307P 2007-06-05 2007-06-05
US93367007P 2007-06-08 2007-06-08
US644908P 2008-01-14 2008-01-14
US6476108P 2008-03-25 2008-03-25

Publications (1)

Publication Number Publication Date
PT2164993T true PT2164993T (pt) 2017-01-12

Family

ID=40094346

Family Applications (1)

Application Number Title Priority Date Filing Date
PT87697611T PT2164993T (pt) 2007-05-29 2008-05-28 Métodos para produção e usos de populações de células multipotentes, populações de células pluripotentes, populações de célula diferenciadas e populações de células resistentes a vih

Country Status (15)

Country Link
US (1) US20110217274A1 (pt)
EP (2) EP2164993B1 (pt)
JP (2) JP2010528613A (pt)
CN (2) CN101772580B (pt)
AU (1) AU2008260187A1 (pt)
BR (1) BRPI0810949A2 (pt)
CA (1) CA2725953A1 (pt)
ES (1) ES2612538T3 (pt)
HU (1) HUE030872T2 (pt)
IL (2) IL202401A (pt)
PL (1) PL2164993T3 (pt)
PT (1) PT2164993T (pt)
RU (2) RU2535365C2 (pt)
SG (2) SG10201509679XA (pt)
WO (1) WO2008150814A2 (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008007654A (es) 2005-12-13 2008-09-26 Univ Kyoto Factor de reprogramacion nuclear.
US8129187B2 (en) 2005-12-13 2012-03-06 Kyoto University Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
CN101743306A (zh) 2007-03-23 2010-06-16 威斯康星校友研究基金会 体细胞重编程
US11859168B2 (en) * 2007-05-29 2024-01-02 Christopher B. REID Electroporation, developmentally-activated cells, pluripotent-like cells, cell reprogramming and regenerative medicine
US9213999B2 (en) 2007-06-15 2015-12-15 Kyoto University Providing iPSCs to a customer
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
JP5346925B2 (ja) 2008-05-02 2013-11-20 国立大学法人京都大学 核初期化方法
DK2297307T3 (en) 2008-06-04 2016-07-25 Cellular Dynamics Int Inc PROCEDURES FOR THE MANUFACTURE OF IPS CELLS USING NON-VIRAL METHODS
EP3330371A1 (en) * 2008-08-12 2018-06-06 Cellular Dynamics International, Inc. Methods for the production of ips cells
JP2010148440A (ja) * 2008-12-25 2010-07-08 Japan Health Science Foundation 組換えアデノウイルス迅速構築システム
WO2010127166A2 (en) 2009-04-30 2010-11-04 The Regents Of The University Of California Combination anti-hiv vectors, targeting vectors, and methods of use
US9365866B2 (en) * 2009-06-03 2016-06-14 National Institute Of Advanced Industrial Science And Technology Vectors for generating pluripotent stem cells and methods of producing pluripotent stem cells using the same
US9453205B2 (en) * 2009-10-31 2016-09-27 Genesis Technologies Limited Methods for reprogramming cells and uses thereof
US20130097717A1 (en) * 2010-06-23 2013-04-18 Vivoscript, Inc. Compositions and methods for re-programming cells without genetic modification for treatment of cardiovascular diseases
AU2011311344B2 (en) 2010-10-08 2016-09-08 Mina Therapeutics Limited Short RNA molecules
WO2012061075A2 (en) * 2010-10-25 2012-05-10 The Regents Of The University Of California Hiv resistant and functional hematopoietic stem/progenitor cells and macrophages from induced pluripotent stem cells
JP6073795B2 (ja) * 2010-10-27 2017-02-01 カッパーアールエヌエー，インコーポレイテッド インターフェロン関連発生制御因子１（ｉｆｒｄ１）への天然アンチセンス転写物の阻害によるｉｆｒｄ１関連疾患の治療
KR102196339B1 (ko) * 2011-12-05 2020-12-29 팩터 바이오사이언스 인크. 세포를 형질감염시키는 방법들 및 생성물들
CN102659951A (zh) * 2012-05-29 2012-09-12 西安医学院 一种TAT结构域修饰的neurogenin2融合蛋白制备方法和用途
WO2014035433A1 (en) * 2012-08-31 2014-03-06 Jan Nolta Genetically modified msc and therapeutic methods
US20140065110A1 (en) 2012-08-31 2014-03-06 The Regents Of The University Of California Genetically modified msc and therapeutic methods
US9663564B2 (en) 2013-03-15 2017-05-30 The Regents Of The University Of California Vectors and methods to treat ischemia
US20140271923A1 (en) 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
CA2930973A1 (en) 2013-11-22 2015-05-28 Pal SAERTROM C/ebp alpha short activating rna compositions and methods of use
LT3268480T (lt) * 2015-03-09 2021-07-26 Sinai Health System Priemonės ir būdai, skirti panaudoti ląstelių dalijimosi lokusus ląstelių proliferacijos kontroliavimui
MA42312A (fr) 2015-07-02 2018-05-09 Medigen Inc Particules de type virus recombinantes utilisant la protéine gag du virus de l'immunodéficience bovine
JP6890831B2 (ja) * 2015-07-08 2021-06-18 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド Ｈｉｖ予備免疫化および免疫療法
JP6841609B2 (ja) 2015-07-10 2021-03-10 ３スキャン インコーポレイテッド 組織学的染色の空間的多重化
TWI808934B (zh) 2015-12-31 2023-07-21 美商伯克利之光生命科技公司 經工程化以表現促發炎多肽之腫瘤浸潤細胞
WO2017160991A1 (en) 2016-03-16 2017-09-21 Lavieu Gregory G Methods, systems and devices for selection and generation of genome edited clones
CA3066107A1 (en) * 2016-06-03 2017-12-07 Hough Ear Institute Combination therapies for inner ear sensory hair cell regeneration/replacement
CN106086075B (zh) * 2016-06-23 2019-08-06 福建医科大学 CXCR4RNAi慢病毒载体的构建方法
KR20230074294A (ko) * 2016-07-19 2023-05-26 유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 Stat3를 타겟으로 하는 종양용해성 바이러스
CN106497882A (zh) * 2016-10-29 2017-03-15 复旦大学 同时过表达R‑spondin1和Noggin的细胞株及其构建方法和应用
CA3048645A1 (en) 2016-12-30 2018-07-05 The Regents Of The University Of California Methods for selection and generation of genome edited t cells
CN108977463A (zh) * 2017-05-31 2018-12-11 伯仕利生物科技发展（盐城）有限公司 一种用于抑制生产用干细胞分化的技术方法
WO2019156216A1 (ja) * 2018-02-09 2019-08-15 国立大学法人京都大学 心筋細胞増殖促進剤及びその利用
US20210095258A1 (en) * 2018-02-22 2021-04-01 Celularity Inc. Post partum tissue-derived induced pluripotent stem cells and uses thereof
CN108715868A (zh) * 2018-05-31 2018-10-30 深圳市免疫基因治疗研究院 一种Gaucher慢病毒载体、慢病毒及其制备方法和应用
CN111484977B (zh) * 2019-01-25 2023-05-16 中国科学院脑科学与智能技术卓越创新中心 重编程产生功能性去甲肾上腺素能神经元的方法
CN110055224B (zh) * 2019-04-03 2023-06-30 深圳市体内生物医药科技有限公司 一种基因修饰的免疫细胞及其制备方法和应用
CN110283779A (zh) * 2019-07-17 2019-09-27 吉林省农业科学院 一种鸡胚胎干细胞的分离培养方法及培养基
MX2023003656A (es) * 2020-09-29 2023-06-22 Neuexcell Therapeutics Inc Vector dlx2.
CN118086341B (zh) * 2024-04-25 2024-08-02 上海凌医生物科技有限公司 在肝脏中高表达人源葡萄糖脑苷脂酶基因的表达框

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2395698A (en) 1943-12-18 1946-02-26 Walter J Mathieu Electric switch
US4361552A (en) 1980-09-26 1982-11-30 Board Of Regents, The University Of Texas System Wound dressing
US5032508A (en) 1988-09-08 1991-07-16 Marrow-Tech, Inc. Three-dimensional cell and tissue culture system
US4956178A (en) 1988-07-11 1990-09-11 Purdue Research Foundation Tissue graft composition
US4902508A (en) 1988-07-11 1990-02-20 Purdue Research Foundation Tissue graft composition
JP2710967B2 (ja) * 1988-11-22 1998-02-10 株式会社日立製作所 集積回路装置の製造方法
US7479269B2 (en) 1988-11-23 2009-01-20 Genetics Institute, Llc Methods for selectively enriching TH1 and TH2 cells
US5281422A (en) 1991-09-24 1994-01-25 Purdue Research Foundation Graft for promoting autogenous tissue growth
US5453357A (en) 1992-10-08 1995-09-26 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
DE69434447T2 (de) 1993-06-07 2006-05-18 Vical, Inc., San Diego Für die gentherapie verwendbare plasmide
US6217867B1 (en) 1993-09-13 2001-04-17 University Of Pittsburgh Non-lethal methods for conditioning a recipient for bone marrow transplantation
US6432711B1 (en) * 1993-11-03 2002-08-13 Diacrin, Inc. Embryonic stem cells capable of differentiating into desired cell lines
US5928944A (en) 1994-02-04 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method of adenoviral-medicated cell transfection
US5484720A (en) 1994-09-08 1996-01-16 Genentech, Inc. Methods for calcium phosphate transfection
JP3351471B2 (ja) 1994-11-29 2002-11-25 タカラバイオ株式会社 形質転換細胞の製造方法
US5554389A (en) 1995-04-07 1996-09-10 Purdue Research Foundation Urinary bladder submucosa derived tissue graft
US5677139A (en) 1995-04-21 1997-10-14 President And Fellows Of Harvard College In vitro differentiation of CD34+ progenitor cells into T lymphocytes
GB9518606D0 (en) * 1995-09-12 1995-11-15 Inst Of Psychiatry Neural transplantation
US5783566A (en) 1996-05-10 1998-07-21 California Institute Of Technology Method for increasing or decreasing transfection efficiency
DE69725592T2 (de) 1996-08-23 2004-08-05 Cook Biotech, Inc., West Lafayette Verfahren zur gewinnung einer gereignigten matrix auf kollagenbasis aus submukosa gewebe
WO1998025636A1 (en) 1996-12-10 1998-06-18 Purdue Research Foundation Stomach submucosa derived tissue graft
CA2286655C (en) 1997-04-11 2009-02-24 Cryolife, Inc. Tissue decellularization
EP1017797B1 (en) * 1997-09-24 2005-06-22 The Regents Of The University Of California Non-primate lentiviral vectors and packaging systems
US6734018B2 (en) 1999-06-07 2004-05-11 Lifenet Process for decellularizing soft-tissue engineered medical implants, and decellularized soft-tissue medical implants produced
EP1210046A4 (en) 1999-06-22 2007-05-02 Res Dev Foundation IMPROVED DRESSING THAT CAN ACCELERATE THE HEALING OF INJURIES
US6479064B1 (en) 1999-12-29 2002-11-12 Children's Medical Center Corporation Culturing different cell populations on a decellularized natural biostructure for organ reconstruction
US6376244B1 (en) 1999-12-29 2002-04-23 Children's Medical Center Corporation Methods and compositions for organ decellularization
EP1315796B1 (en) 2000-08-16 2006-07-12 Duke University Decellularized tissue engineered constructs and tissues
US6733993B2 (en) * 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
WO2002024244A2 (en) 2000-09-20 2002-03-28 Regeneration Technologies, Inc. Method of preparing and processing transplant tissue
US6995013B2 (en) 2002-07-08 2006-02-07 Biomed Solutions, Llc Cell-scaffold composition containing five layers
US7211247B2 (en) 2001-04-09 2007-05-01 University Of Southern California Lentivirus vectors for gene transfer to alveolar epithelial cells
WO2003002165A1 (en) 2001-06-28 2003-01-09 Cook Biotech Incorporated Graft prosthesis devices containing renal capsule collagen
WO2003020191A1 (en) 2001-09-04 2003-03-13 University Of Iowa Research Foundation Cellulose membranes for biodegradable scaffolds
US20030109037A1 (en) * 2001-09-24 2003-06-12 Reid Christopher Brian Methods for application of genetically-modified endogenous or exogenous stem/progenitor or their progeny for treatment of disease
US20030099621A1 (en) 2001-11-29 2003-05-29 Robert Chow Stem cell screening and transplantation therapy for HIV infection
US7297540B2 (en) 2002-01-15 2007-11-20 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods of generating tissue using devitalized, acellular scaffold matrices derived from micro-organs
WO2003070084A2 (en) 2002-02-19 2003-08-28 Bioarttis, Inc. Artificial vessel scaffold and artificial organs therefrom
US7763722B2 (en) * 2003-01-17 2010-07-27 University Of Florida Research Foundation, Inc. Small interference RNA gene therapy
KR101376013B1 (ko) 2005-08-26 2014-03-19 리전츠 오브 더 유니버스티 오브 미네소타 기관 및 조직의 세포제거 및 재세포화
MX2008007654A (es) * 2005-12-13 2008-09-26 Univ Kyoto Factor de reprogramacion nuclear.

Also Published As

Publication number Publication date
SG10201903161XA (en) 2019-05-30
RU2535365C2 (ru) 2014-12-10
WO2008150814A3 (en) 2009-02-05
CN105586358A (zh) 2016-05-18
RU2009148666A (ru) 2011-07-10
WO2008150814A2 (en) 2008-12-11
EP2164993A2 (en) 2010-03-24
US20110217274A1 (en) 2011-09-08
EP2164993B1 (en) 2016-09-21
JP2015077132A (ja) 2015-04-23
RU2718536C2 (ru) 2020-04-08
IL202401A (en) 2015-10-29
IL241906B (en) 2021-07-29
IL202401A0 (en) 2011-08-01
AU2008260187A1 (en) 2008-12-11
CN105586358B (zh) 2020-08-25
PL2164993T4 (pl) 2017-08-31
EP3128015A2 (en) 2017-02-08
ES2612538T3 (es) 2017-05-17
EP3128015A3 (en) 2017-05-03
CA2725953A1 (en) 2008-12-11
EP2164993A4 (en) 2011-04-13
PL2164993T3 (pl) 2017-08-31
JP2010528613A (ja) 2010-08-26
CN101772580B (zh) 2015-11-25
CN101772580A (zh) 2010-07-07
BRPI0810949A2 (pt) 2015-10-27
WO2008150814A8 (en) 2009-07-30
RU2014139904A3 (pt) 2018-06-28
SG10201509679XA (en) 2015-12-30
RU2014139904A (ru) 2016-04-20
IL241906A0 (en) 2015-11-30
HUE030872T2 (en) 2017-06-28

Similar Documents

Publication Publication Date Title
IL202401A0 (en) Methods for production and uses of multipotent cell populations, pluripotent cell populations, differentiated cell populations, and hiv -resistant cell populations
IL283597A (en) A pluripotent stem cell growth medium containing human serum and without a nutrient layer
ZA200908904B (en) Multipotent/pluripotent cells and methods
HK1247954A1 (zh) 由人類多能幹細胞產生間充質幹細胞的方法以及通過所述方法產生的間充質幹細胞
ZA201606403B (en) Pluripotent stem cell culture on micro-carriers
EP2450032A4 (en) MICROVESICLES FROM NUCLEIED MAMMALIAN CELLS AND USE THEREOF
ZA201008391B (en) Pluripotent cells
ZA201001436B (en) Pluripotent stem cell differentiation by using human feeder cells
ZA201100758B (en) Differentiation of pluripotent stem cells
EP2457998A4 (en) METHODS FOR OBTAINING HEPATIC CELLS, HEPATIC ENDODERM CELLS, AND HEPATIC PRECURSOR CELLS BY INDUCING THE DIFFERENTIATION
ZA201000715B (en) Single pluripotent stem cell culture
IL210638A0 (en) Production of pluripotent cells through inhibition of bright/arid3a function
IL209343A (en) Adult nucleotide erythrocytes are separated in vitro, their use and methods for their preparation
PL2254586T3 (pl) Cząstki mezenchymalnych komórek macierzystych
EP2421651A4 (en) MULTIPLEX ANALYSIS OF CELLS, PARTICLES AND OTHER ANALYTES
IL216871A0 (en) Methods, systems, and compositions for neuronal differentiation of multipotent stromal cells
WO2010111659A8 (en) Tumor-initiating cells and methods for using same
EP2294182A4 (en) CULTS OF MULTIPOTENT STEM CELLS
EP2376625A4 (en) PLURIPOTENT CELLS DERIVED FROM STOMATIC CELLS AND METHODS OF USE
GB2458429B (en) Novel mesenchymal progenitor cells derived from human blastocyst-derived stem cells
ZA201000014B (en) Methods for production and uses of multipotent cell populations
GB0808280D0 (en) Methods of preparing cell populations
GB0911184D0 (en) In vitro methods for the preparation of differentiated haematopoietic cells and uses thereof